STAT+: PBMs Warn Trump’s Proposal to Disclose Drug Prices Is Illegal

Why It Matters

Transparent drug‑pricing data could curb rising prescription costs and reshape employer benefit strategies, while the legal battle may set precedents for future health‑policy regulation.

Key Takeaways

• DOL rule forces PBMs to reveal pricing data to employers
• PBMs claim the disclosure mandate violates federal law
• Health insurers fear profit loss from increased transparency
• Mark Cuban backs rule to increase PBM accountability
• Pharma backs PBM focus but shields its own pricing

Pulse Analysis

Pharmacy benefit managers sit at the intersection of insurers, drug manufacturers, and employers, negotiating rebates and formularies that ultimately affect the price patients pay at the pharmacy counter. By mandating that PBMs disclose the full spectrum of pricing data—including rebates, spread pricing, and administrative fees—to employers, the Department of Labor aims to demystify a market that has long been described as a "black box." Greater visibility could empower large employers to negotiate more favorable contracts, potentially lowering out‑of‑pocket costs for millions of workers.

The proposal, however, has ignited a fierce legal and political backlash. PBMs and health insurers argue that the rule oversteps the Department of Labor’s authority and infringes on proprietary business information protected under trade‑secret statutes. Their lobbying effort, reflected in over 500 public comments, warns that forced disclosure could destabilize existing rebate structures and trigger costly litigation. At the same time, pharmaceutical companies are playing a nuanced game: they welcome scrutiny of PBM practices that have been blamed for inflating drug spend, yet they resist any move that would compel manufacturers to reveal their own pricing strategies.

If the rule survives legal challenges, its impact could ripple across the healthcare ecosystem. Employers would gain a data‑driven lever to demand lower drug spend, insurers might renegotiate contracts, and PBMs could be forced to adopt more transparent pricing models. Conversely, a setback could reinforce the status quo, preserving opaque pricing and limiting the ability of employers to control prescription costs. Stakeholders are watching closely, as the outcome will shape the balance of power between payers, PBMs, and drug makers for years to come.